Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Hydrochlorothiazide use and risk of Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Real-world drug survival of ixekizumab for psoriasis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Hydrochlorothiazide use has been associated with markedly increased risk of squamous cell carcinoma. No previous studies have investigated the association between hydrochlorothiazide use and the risk of Merkel cell carcinoma (MCC) and malignant adnexal skin tumors (MAST).

OBJECTIVE: To examine the association between hydrochlorothiazide use and the risk of MCC and MAST.

METHODS: Using Danish nationwide health registries, we identified all patients with incident MCC or MAST during 2004-2015 and matched cases individually to cancer-free population controls by risk set sampling. Using conditional logistic regression, we estimated odds ratios (ORs) associated with cumulative use of hydrochlorothiazide.

RESULTS: The adjusted ORs for MCC and MAST associated with high use (≥50,000 mg) of hydrochlorothiazide was 2.3 (95% CI, 1.1-4.8) and 3.6 (95% CI, 1.9-7.0), respectively, increasing to 3.3 (95% CI 1.3-8.3) and 5.6 (95% CI 2.4-13.3) with highest use (≥100,000mg). We found no increase in risk of the tumors in analyses of drugs with similar indications as hydrochlorothiazide, except a tendency toward an increased risk of MCC associated with use of furosemide (OR 1.9, 95% CI 0.9-4.0).

LIMITATIONS: No data on sun exposure was available.

CONCLUSIONS: Hydrochlorothiazide use is associated with an increased risk of MCC and MAST.

OriginalsprogEngelsk
TidsskriftJournal of the American Academy of Dermatology
Vol/bind80
Udgave nummer2
Sider (fra-til)460-465
Antal sider6
ISSN0190-9622
DOI
StatusUdgivet - 15 feb. 2019

ID: 55578625